← Back to Search
Studies Of The HER-2/neu Proto-oncogene In Human Breast And Ovarian Cancer.
D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong, D. Keith, W. Levin, S. Stuart, J. Udove, A. Ullrich
Published 1989 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/neu in breast and ovarian cancer, including a similar incidence of amplification, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/neu in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers.
This paper references
Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.
D. Zhou (1989)
The molecular genetics of cellular oncogenes.
H. Varmus (1984)
OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION
DeonJ. Venter (1987)
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Alan L. Schechter (1984)
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
L. Coussens (1985)
The influence of protease digestion and duration of fixation on the immunostaining of keratins. A comparison of formalin and ethanol fixation.
H. Battifora (1986)
Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor.
M. Press (1988)
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
R. Hudziak (1987)
Amplification of c-erbB-2 and aggressive human breast tumors?
D. Slamon (1988)
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
C. Shih (1981)
Proto-oncogenes and human cancers.
D. Slamon (1987)
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
M. Berger (1988)
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
D. Zhou (1987)
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. D. Di Fiore (1987)
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
W. Muller (1988)
Cellular oncogenes and retroviruses.
J. Bishop (1983)
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
C. Bargmann (1986)
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
J. Varley (1987)
Immunocytochemical identification of estrogen receptor in ovarian carcinomas. Localization with monoclonal estrophilin antibodies compared with biochemical assays.
M. Press (1985)
c-erbB-2 expression in benign and malignant breast disease.
B. Gusterson (1988)
Expression of cellular oncogenes in human malignancies.
D. Slamon (1984)
The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis.
S. Bacus (1988)
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
M. J. van de Vijver (1988)
Estrogen and Progestin Binding in Cytosols of Ovarian Adenocarcinomas
J. Holt (1979)
Amplification and over-expression of the neu oncogene in human breast carcinomas.
M. J. van de Vijver (1988)
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
D. Barnes (1988)
An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin.
M. Press (1984)
Expression of p21 ras oncoproteins in human cancers.
T. Tanaka (1986)
Identification and characterization of the protein encoded by the human N-myc oncogene.
D. Slamon (1986)
Studies of the human c-myb gene and its product in human acute leukemias.
D. Slamon (1986)
In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors?
D. Slamon (1988)
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
C. Wright (1989)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
This paper is referenced by
Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
C. López-Morales (2015)
ERRF sensitizes ERBB 2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL 1 and ERBB 2 expression
Leilei Qi ()
Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions
M. Kankuri-Tammilehto (2012)
Genomic Copy Number Alterations in Serous Ovarian Cancer
Joe R. Delaney (2018)
Cancer Immunology: Bench to Bedside Immunotherapy of Cancers
N. Rezaei (2021)
Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection
Y. Tao (2017)
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
L. Gianni (2010)
ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab
Valentina Agnolon (2020)
Preparation and application of immunoaffinity in-tube solid phase microextraction column with oriented antibody-immobilized porous layer open tubular capillary for high sensitive quantification of serum extracellular domain of human epidermal growth factor receptor 2 levels.
Jianhui Pan (2020)
Progress in the development of a therapeutic vaccine for breast cancer.
A. Coveler (2010)
Targeting IKK in Basal-Like Breast Tumors as a Therapeutic Approach
A. Baldwin (2010)
Microscopy, Immunohistochemistry, and Antigen Retrieval Methods
M. A. Hayat (2002)
Testing for HER2 Status
W. Hanna (2001)
SRC in human carcinogenesis.
Salvatore V Russello (2004)
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
S. Bellone (2003)
Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression.
V. Benoît (2004)
ナノテクノロジーに関与する微粒子製剤の最近の話題 (2) 医薬品
文由 石井 (2004)
Estudio de la expresión de cerbB-2 en el adenocarcinoma de próstata
P. Fraile (2005)
Central nervous system metastases in breast cancer patients administered trastuzumab.
R. Duchnowska (2005)
Transgenic mouse models for the prevention of breast cancer.
Q. Shen (2005)
Bio-feedback treatment of fecal incontinence: where are we, and where are we going?
G. Chiarioni (2005)
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
G. Arpino (2005)
Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents.
G. Zheng (2005)
Role of TGF-β in Tumor Progression and Metastasis
J. Pinkas (2006)
No Amplifications of Hypoxia-Inducible Factor-1α Gene in Invasive Breast Cancer: A Tissue Microarray Study
M. M. Vleugel (2004)
Biological variables and prognosis of DCIS.
M. Vijver (2005)
Herceptin: mechanisms of action and resistance.
R. Nahta (2006)
Molecular analysis of early onset Indonesian breast cancer
D. Purnomosari (2006)
Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21Waf1/Cip1
V. Borgdorff (2010)
Gamma- and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression.
E. Pierpaoli (2010)
The anti-tumourigenic action of the progesterone receptor antagonist Lonaprisan (ZK230211) in breast cancer
L. Busia (2011)
COMPARISON OF CARDIOTOXIC EFFECTS OF DIFFERENT ERB-B2 INHIBITORS AND THEIR
Dottorato Di Ricerca (2011)See more